2008-2009 Influenza Season Week 31 ending August 8, 2009 by National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division.
  
 
2008-2009 Influenza Season 
Week 31 ending August 8, 2009 
All data are preliminary and may change as more reports are received. 
On June 11, the World Health Organization raised the pandemic alert level from Phase 5 to Phase 
6 indicating that an influenza pandemic is underway.   
Synopsis:  During week 31 (August 2-8, 2009), influenza activity decreased slightly in the United 
States; however, there were still higher levels of influenza-like illness than is normal for this time of 
year.   
o A total of 7,511 hospitalizations and 477 deaths associated with novel influenza A (H1N1) 
viruses have been reported to CDC. 
o During week 31: 
o 809 (19.1%) specimens tested by U.S. World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories 
and reported to CDC/Influenza Division were positive for influenza. 
o 98% of all subtyped influenza A viruses being reported to CDC were novel influenza A 
(H1N1) viruses. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o Three influenza-associated pediatric deaths were reported and all were associated with a 
novel influenza A (H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was below national 
and region-specific baseline levels. 
o Four states and Puerto Rico reported geographically widespread influenza activity, 10 
states reported regional influenza activity, 10 states and the District of Columbia reported 
local influenza activity, and 26 states reported sporadic influenza activity. 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 
Novel A 
(H1N1) 
A  
(unable 
to sub-
type)¥ 
A 
(Subty-
ping 
not 
perfor-
med) 
B  Pediatric Deaths 
Nation Normal 19.1% 15 of 52 8,081 2,792 29,153 751 18,190 10,742 101 
Region I Normal 5.6% 1 of 6 583 305 2,873 13 1,693 820 4 
Region II Normal 7.8% 2 of 3 296 228 1,817 21 2,379 714 19 
Region III Normal 21.9% 2 of 6 1,250 219 4,128 20 1,014 1,363 10 
Region IV Normal 23.3% 4 of 8 865 188 1,917 56 3,000 1,251 8 
Region V Normal 16.4% 0 of 6 1,659 204 8,169 191 866 1,421 16 
Region VI Normal 28.6% 0 of 5 828 300 3,185 7 4,609 2,666 15 
Region VII Normal 23.9% 0 of 4 534 83 993 99 524 537 0 
Region VIII Normal 15.5% 1 of 6 533 219 1,342 72 1,695 500 9 
Region IX Normal 19.3% 4 of 4 1,143 726 2,504 59 1,891 779 18 
Region X Normal 28.1% 1 of 4 390 320 2,225 213 519 691 2 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, 
SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, 
NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states, the District of Columbia, and Puerto Rico 
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further testing 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza and 
the number positive by influenza type and subtype. The results of tests performed during the 
current week are summarized in the table below. 
 
 
 Week 31 
No. of specimens tested 4,246 
No. of positive specimens (%) 809 (19.1%) 
Positive specimens by type/subtype  
Influenza A                806 (99.6%) 
          A (novel H1N1)   516 (64.0%)        
          A (subtyping not performed)          264 (32.8%) 
          A (unable to subtype)  14 (1.7%)           
          A (H3)                2 (0.2%)    
          A (H1) 10 (1.2%) 
Influenza B                   3 (0.4%) 
 
 
During week 31, seasonal influenza A (H1) and A (H3) and B viruses co-circulated at low levels with 
novel influenza A (H1N1) viruses.  98% of all subtyped influenza A viruses being reported to CDC 
this week were novel influenza A (H1N1) viruses. 
 
The unusually high percentage of specimens testing positive for influenza by WHO and NREVSS 
collaborating laboratories remained higher during week 31 than is typically seen this time of year, 
and may be due in part to changes in testing practices by health care providers, triaging of 
specimens by public health laboratories, an increase in the number of specimens collected from 
outbreaks, and other factors. 
 
During the 2008-09 influenza season, influenza A (H1), A (H3), and B viruses have co-circulated in 
the United States.  On April 15 and 17, 2009, CDC confirmed the first two cases of novel influenza 
A (H1N1) virus infection in the United States, and this virus has been the predominant circulating 
influenza strain since testing and reporting of novel influenza A (H1N1) viruses by U.S. WHO 
collaborating laboratories began during week 17 (week ending May 2, 2009).  
 
Because of the extensive spread of novel influenza A (H1N1) within the United States, it has 
become extremely resource intensive for local and state health departments to count individual 
cases.  In addition, since only a small proportion of persons with respiratory illness are tested for 
novel influenza A (H1N1) infection, confirmed and probable case counts represent a significant 
underestimate of the true number of novel influenza A (H1N1) cases in the United States.  As a 
result, CDC no longer reports individual case counts; only hospitalizations and deaths associated 
with confirmed novel influenza A (H1N1) are reported each week on the CDC H1N1 influenza 
website (http://www.cdc.gov/h1n1flu/update.htm). 
 
As of August 14, 2009, 7,511 hospitalizations and 477 deaths (10 deaths in individuals 0-4 years, 
67 deaths in individuals 5-24 years, 203 deaths in adults 25-49 years, 135 deaths in adults 50-64 
years, 45 deaths in adults age 65 and older, and 17 deaths with unknown age) associated with 
novel influenza A (H1N1) virus have been identified by CDC and state and local public health 
departments.   
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Antigenic Characterization:  CDC has antigenically characterized 2,036 seasonal human 
influenza viruses [1,186 influenza A (H1), 201 influenza A (H3) and 649 influenza B viruses] 
collected by U.S. laboratories since October 1, 2008, and 280 novel influenza A (H1N1) viruses. 
All 1,186 seasonal influenza A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  One hundred ninety-three (96%) of 201 influenza 
A (H3N2) viruses tested are related to the A (H3N2) vaccine component (A/Brisbane/10/2007) and 
eight viruses (4%) tested showed reduced titers with antisera produced against 
A/Brisbane/10/2007.  
All 280 novel influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference 
virus selected by WHO as a potential candidate for novel influenza A (H1N1) vaccine. 
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Seventy-four (11%) of 649 influenza B viruses 
tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). 
The remaining 575 (89%) viruses belong to the B/Victoria lineage and are not related to the vaccine 
strain.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data are based on hemagglutination inhibition (HI) testing using a panel of 
reference ferret antisera, and results may not correlate with clinical protection against circulating 
viruses provided by influenza vaccination. 
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Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of novel influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 1,142 seasonal influenza A (H1N1), 241 influenza A 
(H3N2), and 646 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Also, 1,148 seasonal influenza A (H1N1) and 235 influenza 
A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine and 
rimantadine).  Three hundred sixteen novel influenza A (H1N1) viruses have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  Three hundred seventy-one 
novel influenza A (H1N1) viruses have been tested for resistance to the adamantanes (amantadine 
and rimantadine).  The results of antiviral resistance testing performed on these viruses are 
summarized in the table below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 1,142 1,137 (99.6%) 0 (0) 1,148 6 (0.5%) 
Influenza A (H3N2) 241 0 (0) 0 (0) 235 235 (100%) 
Influenza B 646 0 (0) 0 (0) N/A* N/A* 
Novel Influenza A  
(H1N1) 318 2 (0.6) 0 (0) 371 371 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
The novel influenza A (H1N1) virus is susceptible to both neuraminidase inhibitor antiviral 
medications zanamivir and oseltamivir.  It is resistant to the adamantane antiviral medications, 
amantadine and rimantadine. Antiviral treatment with either oseltamivir or zanamivir is 
recommended for all patients with confirmed, probable or suspected cases of novel influenza A 
(H1N1) virus infection who are hospitalized or who are at higher risk for seasonal influenza 
complications.   
 
Rare sporadic cases of oseltamivir resistant novel influenza A (H1N1) viruses have been detected 
worldwide, including two viruses in the United States.  Additional information on antiviral 
recommendations for treatment and chemoprophylaxis of novel influenza A (H1N1) infection is 
available at http://www.cdc.gov/h1n1flu/recommendations.htm. 
 
Three seasonal influenza A (H1N1) viruses collected between February 8 and May 11, 2009, were 
found to be resistant to both oseltamivir and the adamantanes (amantadine and rimantadine).  All 
seasonal influenza A (H1N1) viruses tested retain their sensitivity to zanamivir.  The three dually-
resistant viruses represent less than 1% of all seasonal influenza A (H1N1) viruses tested during 
the 2008-09 influenza season, and as a result, no changes to the influenza antiviral treatment or 
prophylaxis recommendations will be made at this time.  CDC will continue to monitor trends in 
antiviral resistance over the summer and throughout the upcoming 2009-10 influenza season.   
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 31, 6.1% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 6.3% for week 31. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending 8/08/2009 
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Influenza-Associated Pediatric Mortality:  Three influenza-associated pediatric deaths were 
reported to CDC during week 31 (Arizona, Mississippi, and Utah).  These deaths were associated 
with novel influenza A (H1N1) virus infection.  The deaths reported this week occurred between 
June 14 and August 1, 2009.  Since September 28, 2008, CDC has received 101 reports of 
influenza-associated pediatric deaths that occurred during the current influenza season, 33 of which 
were due to novel influenza A (H1N1) virus infections. 
 
Of the 42 children who had specimens collected for bacterial culture from normally sterile sites, 16 
(38.1%) were positive; Staphylococcus aureus was identified in 10 (62.5%) of the 16 children.    
Four of the S. aureus isolates were sensitive to methicillin and six were methicillin resistant.   
Fourteen (87.5%) of the 16 children with bacterial coinfections were five years of age or older and 
10 (62.5%) of the 16 children were 12 years of age or older.  Eleven (33.3%) of the 33 children with 
confirmed novel influenza A (H1N1) infection had a specimen collected from a normally sterile site; 
two (18.2%) of the 11 children had a positive bacterial culture (methicillin resistant S. aureus and 
Streptococcus constellatus).  An increase in the number of influenza-associated pediatric deaths 
with bacterial coinfections was first recognized during the 2006-07 influenza season.  In January 
2008, interim testing and reporting recommendations were released regarding influenza and 
bacterial coinfections in children and are available at 
(http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268). 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
 
During October 12, 2008 to July 11, 2009, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 4.42 per 10,000. 
Because of case identification methods utilized in this study, there is a delay from the date of 
hospitalization to the date of report.  
 
Data collection for influenza-associated hospitalizations through the NVSN has been completed for 
the 2008-09 influenza season.  There will be no updates to this system after week 28 (the week 
ending July 18, 2009). 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During April 15, 2009 to August 8, 2009, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by the EIP (rates include type A, type B, 
and novel H1N1): 
 
Rates for children aged 0-23 months, 2-4 years, and 5-17 years were 2.0, 0.8, and 0.6 per 10,000, 
respectively.  Rates for adults aged 18-49 years, 50-64 years, and ≥ 65 years were 0.4, 0.5, and 0.4 
per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
Spring/Summer 2009 
*This value represents an age group-specific average influenza rate from October 1 to 
April 30 from the 2005-06, 2006-07, and 2007-08 influenza seasons.
**Note: The scales for the 0-23 month and the ≥65 year age groups differ from other age 
groups. 
**
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Outpatient Illness Surveillance: Nationwide during week 31, 1.1% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.2% to 1.9%. All 10 
regions reported percentages of visits for ILI below their respective region-specific baselines.  ILI 
decreased during week 31 in eight of 10 regions compared to week 30.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 31, the following influenza activity was reported: 
 Widespread influenza activity was reported by Puerto Rico and four states (Alaska, Hawaii, 
Maine, and South Carolina). 
 Regional influenza activity was reported by 10 states (Arizona, California, Florida, Georgia, 
Maryland, Montana, Nevada, New Jersey, North Carolina, and West Virginia). 
 Local influenza activity was reported by the District of Columbia and 10 states (Arkansas, 
Connecticut, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas, Virginia, 
Washington, and Wyoming). 
 Sporadic activity was reported by 26 states (Alabama, Colorado, Delaware, Idaho, Illinois, 
Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Nebraska, 
New Hampshire, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Rhode 
Island, South Dakota, Utah, Vermont, and Wisconsin). 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: August 14, 2009.  
 
